Literature DB >> 15866553

Sensitized attentional performance and Fos-immunoreactive cholinergic neurons in the basal forebrain of amphetamine-pretreated rats.

Vicente Martinez1, Vinay Parikh, Martin Sarter.   

Abstract

BACKGROUND: The consequences of repeated exposure to psychostimulants have been hypothesized to model aspects of schizophrenia. This experiment assessed the consequences of the administration of an escalating dosing regimen of amphetamine (AMPH) on attentional performance. Fos-like immunoreactivity (Fos-IR) in selected regions of these rats' brains was examined to test the hypothesis that AMPH-sensitized attentional impairments are associated with increased recruitment of basal forebrain cholinergic neurons.
METHODS: Rats were trained in a sustained attention task and then treated with saline or in accordance with an escalating dosing regimen of AMPH (1-10 mg/kg). Performance was assessed during the pretreatment and withdrawal periods and following the subsequent administration of AMPH "challenges" (.5, 1.0 mg/kg). Brain sections were double-immunostained to visualize Fos-IR and cholinergic neurons.
RESULTS: Compared with the acute effects of AMPH, AMPH "challenges," administered over 2 months after the pretreatment was initiated, resulted in significant impairments in attentional performance. In AMPH-pretreated and -challenged animals, an increased number of Fos-IR neurons was observed in the basal forebrain. The majority of these neurons were cholinergic.
CONCLUSIONS: The evidence supports the hypothesis that abnormally regulated cortical cholinergic inputs represent an integral component of neuronal models of the attentional dysfunctions of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15866553     DOI: 10.1016/j.biopsych.2005.02.005

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  13 in total

1.  Persistent alterations in cognitive function and prefrontal dopamine D2 receptors following extended, but not limited, access to self-administered cocaine.

Authors:  Lisa A Briand; Shelly B Flagel; M Julia Garcia-Fuster; Stanley J Watson; Huda Akil; Martin Sarter; Terry E Robinson
Journal:  Neuropsychopharmacology       Date:  2008-02-27       Impact factor: 7.853

2.  mGluR7 genetics and alcohol: intersection yields clues for addiction.

Authors:  Beatrix Gyetvai; Agnes Simonyi; Melinda Oros; Mariko Saito; John Smiley; Csaba Vadász
Journal:  Neurochem Res       Date:  2011-03-30       Impact factor: 3.996

Review 3.  Deficits in attentional control: cholinergic mechanisms and circuitry-based treatment approaches.

Authors:  Martin Sarter; Giovanna Paolone
Journal:  Behav Neurosci       Date:  2011-12       Impact factor: 1.912

4.  Basal forebrain subcortical projections.

Authors:  Lindsay J Agostinelli; Joel C Geerling; Thomas E Scammell
Journal:  Brain Struct Funct       Date:  2019-01-05       Impact factor: 3.270

5.  Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus.

Authors:  Ming Li; Wei He; Alexa Mead
Journal:  Behav Pharmacol       Date:  2009-02       Impact factor: 2.293

Review 6.  CNTRICS final task selection: control of attention.

Authors:  Keith H Nuechterlein; Steven J Luck; Cindy Lustig; Martin Sarter
Journal:  Schizophr Bull       Date:  2009-01       Impact factor: 9.306

7.  c-Fos protein expression is increased in cholinergic neurons of the rodent basal forebrain during spontaneous and induced wakefulness.

Authors:  J T McKenna; J W Cordeira; B A Jeffrey; C P Ward; S Winston; R W McCarley; R E Strecker
Journal:  Brain Res Bull       Date:  2009-08-28       Impact factor: 4.077

Review 8.  Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.

Authors:  Wayne C Drevets; Carlos A Zarate; Maura L Furey
Journal:  Biol Psychiatry       Date:  2012-11-28       Impact factor: 13.382

Review 9.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

Review 10.  A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia.

Authors:  Martin Sarter; Vicente Martinez; Rouba Kozak
Journal:  Psychopharmacology (Berl)       Date:  2008-07-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.